Ronghui Xia1, Rongrui Zhou, Zhen Tian, Chunye Zhang, Lizhen Wang, Yuhua Hu, Jing Han, Jiang Li. 1. From the Department of Oral Pathology, 9th People's Hospital, Shanghai Jiao Tong University, School of Medicine, Shanghai Key Laboratory of Stomatology, Shanghai, China (Drs Xia, Tian, Zhang, Wang, Hu, Han, and Li); the Department of Oncology and Diagnostic Sciences, Dental School, University of Maryland, Baltimore, Maryland (Dr Xia); and the Department of Oral Medicine, Shanghai Stomatological Disease Center, Shanghai, China (Dr Zhou). Ronghui Xia and Rongrui Zhou contributed equally to this work.
Abstract
CONTEXT: Histone methylation and acetylation play important roles in the carcinogenesis and progression of cancer. OBJECTIVE: To investigate whether histone modifications influence the prognosis of patients with salivary adenoid cystic carcinoma (ACC). DESIGN: The expression of histone H3 lysine 9 trimethylation (H3K9me3) and histone H3 lysine 9 acetylation (H3K9Ac) was assessed by immunohistochemistry in 66 specimens of primary ACC. Tests were used to determine the presence of any correlation between H3K9me3 and H3K9Ac levels and clinicopathologic parameters. Log-rank test and Cox proportional hazards regression models were used to analyze the survival data. RESULTS: H3K9me3 expression was positively correlated with solid pattern tumors (P = .002) and distant metastasis (P = .001). Solid pattern tumors had lower H3K9Ac expression levels than cribriform-tubular pattern tumors (P = .03). Patients whose tumors showed high H3K9me3 expression and a solid pattern had a significantly poorer overall survival (OS) (P < .001 and P < .001, respectively) and disease-free survival (P < .001 and P = .01, respectively). Low H3K9Ac expression was correlated with poor OS (P = .05). The multivariate analysis indicated that high levels of H3K9me3 expression and solid pattern tumors were independent prognostic factors that significantly influenced OS (P = .004 and P = .04, respectively). H3K9me3 expression was identified as the only independent predictor of disease-free survival (P = .006). CONCLUSIONS: Our results suggest that high levels of H3K9me3 expression are predictive of rapid cell proliferation and distant metastasis in ACC. Compared with histologic patterns, H3K9me3 might be a better predictive biomarker for the prognosis of patients with salivary ACC.
CONTEXT: Histone methylation and acetylation play important roles in the carcinogenesis and progression of cancer. OBJECTIVE: To investigate whether histone modifications influence the prognosis of patients with salivary adenoid cystic carcinoma (ACC). DESIGN: The expression of histone H3 lysine 9 trimethylation (H3K9me3) and histone H3 lysine 9 acetylation (H3K9Ac) was assessed by immunohistochemistry in 66 specimens of primary ACC. Tests were used to determine the presence of any correlation between H3K9me3 and H3K9Ac levels and clinicopathologic parameters. Log-rank test and Cox proportional hazards regression models were used to analyze the survival data. RESULTS: H3K9me3 expression was positively correlated with solid pattern tumors (P = .002) and distant metastasis (P = .001). Solid pattern tumors had lower H3K9Ac expression levels than cribriform-tubular pattern tumors (P = .03). Patients whose tumors showed high H3K9me3 expression and a solid pattern had a significantly poorer overall survival (OS) (P < .001 and P < .001, respectively) and disease-free survival (P < .001 and P = .01, respectively). Low H3K9Ac expression was correlated with poor OS (P = .05). The multivariate analysis indicated that high levels of H3K9me3 expression and solid pattern tumors were independent prognostic factors that significantly influenced OS (P = .004 and P = .04, respectively). H3K9me3 expression was identified as the only independent predictor of disease-free survival (P = .006). CONCLUSIONS: Our results suggest that high levels of H3K9me3 expression are predictive of rapid cell proliferation and distant metastasis in ACC. Compared with histologic patterns, H3K9me3 might be a better predictive biomarker for the prognosis of patients with salivary ACC.
Authors: Safina Ali; Robert Bryant; Frank L Palmer; Monica DiLorenzo; Jatin P Shah; Snehal G Patel; Ian Ganly Journal: Ann Surg Oncol Date: 2015-03-06 Impact factor: 5.344
Authors: Szofia Hajósi-Kalcakosz; Eszter Vincze; Katalin Dezső; Sándor Paku; András Rókusz; Zoltán Sápi; Erika Tóth; Péter Nagy Journal: Diagn Pathol Date: 2015-09-17 Impact factor: 2.644
Authors: Anne Benard; Inès J Goossens-Beumer; Anneke Q van Hoesel; Wouter de Graaf; Hamed Horati; Hein Putter; Eliane C M Zeestraten; Cornelis J H van de Velde; Peter J K Kuppen Journal: BMC Cancer Date: 2014-07-22 Impact factor: 4.430
Authors: Lucas de Lima Maia; Gabriela Tonini Peterle; Marcelo Dos Santos; Leonardo Oliveira Trivilin; Suzanny Oliveira Mendes; Mayara Mota de Oliveira; Joaquim Gasparini Dos Santos; Elaine Stur; Lidiane Pignaton Agostini; Cinthia Vidal Monteiro da Silva Couto; Juliana Dalbó; Aricia Leone Evangelista Monteiro de Assis; Anderson Barros Archanjo; Ana Maria Da Cunha Mercante; Rossana Veronica Mendoza Lopez; Fábio Daumas Nunes; Marcos Brasilino de Carvalho; Eloiza Helena Tajara; Iúri Drumond Louro; Adriana Madeira Álvares-da-Silva Journal: PLoS One Date: 2018-03-28 Impact factor: 3.240
Authors: Abdullah Al Emran; Diego M Marzese; Dinoop Ravindran Menon; Mitchell S Stark; Joachim Torrano; Heinz Hammerlindl; Gao Zhang; Patricia Brafford; Matthew P Salomon; Nellie Nelson; Sabrina Hammerlindl; Deepesh Gupta; Gordon B Mills; Yiling Lu; Richard A Sturm; Keith Flaherty; Dave S B Hoon; Brian Gabrielli; Meenhard Herlyn; Helmut Schaider Journal: Oncotarget Date: 2017-12-24